V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Recursion Pharmaceuticals Executive Compensation (FY25)

RXRX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Najat Khan
Latest say-on-pay support
=
June 17, 2026
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The Recursion Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 19, 2026Latest filing (8-K): June 18, 2026
7 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Recursion Pharmaceuticals brief$1,500Get the executive brief
Velarion Member, one year
214 figures on this page: 211 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Najat Khan: $9,194,805 → $5,349,065 (41.8% lower)
Say-on-pay support: 98.7% → 87.0% (11.7 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Recursion Pharmaceuticals' chief executive and what were they paid?
Najat Khan was paid $5,349,065 in total compensation as Chief Executive Officer and President for fiscal 2025. Compared with the $9,194,805 reported for fiscal 2024, Khan's total was 41.8% lower.
What was Recursion Pharmaceuticals' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 87.0% of votes cast for or against in favor at the meeting held June 17, 2026.
Which companies are in Recursion Pharmaceuticals' peer group?
The disclosed peer group names AbCellera Biologics, Adaptive Biotechnologies, BridgeBio Pharma, C3.ai and Certara, among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Gibson
Chief Executive Officer
◇—◇◇◇—◇— not reconciled
Tina Marriott Larson
Chief Operating Officer and President
◇—◇◇◇—◇— not reconciled
Michael Secora
Chief Financial Officer
◇—◇◇◇—◇— not reconciled
Shafique Virani
Chief Corporate Development Office
◇—◇◇◇—◇— not reconciled
Ramona Doyle
Chief Medical Officer
◇—◇◇——◇— not reconciled
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Gibson
former Chief Executive Officer and President and current Chair of the Board
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Najat Khan
Chief R&D and Chief Commercial Officer
◇◇◇◇◇—◇◇
Christopher Gibson
Chief Executive Officer
◇—◇◇◇—◇◇
Ben Taylor
Chief Financial Officer and President of Recursion UK
◇—◇◇◇——◇
Tina Marriott
Executive Advisor and Former President and Chief Operating Officer
Departed during or after this year
◇—◇◇◇—◇◇
Michael Secora
Former Chief Financial Officer
Departed during or after this year
◇—◇◇——◇◇
David Mauro
Chief Medical Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Gibson
Former Chief Executive Officer and President and current Chair of the Board
Departed during or after this year
◇—◇◇◇—◇◇
Najat Khan
Chief Executive Officer and President
◇—◇◇◇—◇◇
Ben Taylor
Chief Financial Officer and President of Recursion UK
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Ben TaylorRSU◇——◇——◇
Ben TaylorOPTION◇——◇—◇◇
Christopher GibsonRSU◇——◇——◇
Christopher GibsonOPTION◇——◇—◇◇
Najat KhanOPTION◇——◇—◇◇
Najat KhanOPTION◇——◇—◇◇
Najat KhanRSU◇——◇——◇
Najat KhanRSU◇——◇——◇
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Najat KhanRSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇11/5/2035
Option◇—◇2/3/2035
Option◇—◇8/1/2034
Christopher GibsonRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/3/2035
Option◇—◇2/9/2034
Option◇—◇2/1/2033
Option◇—◇2/4/2032
Ben TaylorRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/3/2035
Option◇—◇12/19/2034
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Ben Taylor
Chief Financial Officer and President of Recursion UK · Employment agreement · citing a 2025 filing
Non-solicit period◇
Christopher Gibson
Former Chief Executive Officer and President and current Chair of the Board · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Elaine Sun
◇◇◇———◇
Namandj Bumpus
◇◇◇———◇
Robert Hershberg
Lead independent director
◇◇◇———◇
Zavain Dar
◇◇◇———◇
Blake Borgeson
◇◇◇———◇
Franziska Michor
◇◇◇———◇
Dean Y. Li
◇◇◇———◇
Zachary Bogue, Najat Khan and Christopher Gibson served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • AbCellera Biologics ABCL
  • Adaptive Biotechnologies ADPT
  • BridgeBio Pharma BBIO
  • C3.ai AI
  • Certara CERT
  • Cytek Biosciences CTKB
  • Denali Therapeutics DNLI
  • Dyne Therapeutics DYN
  • IDEAYA BioSciences IDYA
  • Intapp INTA
  • Relay Therapeutics RLAY
  • Repligen RGEN
  • Rocket Pharmaceuticals RCKT
  • Schrodinger SDGR
  • SoundHound AI SOUN
  • Twist Bioscience TWST

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 17, 2026=◇◇◇
2024June 18, 2025=◇◇◇
2022June 16, 2023=◇◇◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Najat Khan (Chief Executive Officer and President), FY2025 total compensation $5,349,065 (base salary $600,000) [exec_comp, SEC accession 0001601830-26-000065, filed 2026-04-30]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Recursion Pharmaceuticals files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Recursion Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Recursion Pharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Recursion Pharmaceuticals' disclosed peer group is defensible, who names Recursion Pharmaceuticals back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
214 figures on this page: 211 cited to the filing that reported them, 3 calculated from figures it prints.
211 cited to the filing
3 calculated from the filing

Documents cited

  1. 0001601830-26-000080
    Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast: For Against Abstain Broker Non-Votes
  2. 0001601830-26-000065
    Compensation Discussion and Analysis · EXECUTIVE COMPENSATION TABLES · Grants of Plan-Based Awards
  3. 0001601830-25-000088
    Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast: For Against Abstain Broker Non-Votes
  4. 0001601830-25-000062
    Summary Compensation Table for 2024, 2023 and 2022
  5. 0001601830-23-000048
  6. 0001601830-23-000013
    EXECUTIVE COMPENSATION TABLES
  7. 0001601830-25-000035
    EX-10.18
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Recursion Pharmaceuticals executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/RXRX (accessed 2026).
Short form: data: Velarion

The Recursion Pharmaceuticals brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Recursion Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Recursion Pharmaceuticals discloses

The companies named in RXRX's own disclosed peer group.

AbCellera BiologicsAdaptive BiotechnologiesBridgeBio PharmaC3.aiCertaraCytek BiosciencesDenali TherapeuticsDyne TherapeuticsIDEAYA BioSciencesIntappRelay TherapeuticsRepligenRocket PharmaceuticalsSchrodingerSoundHound AITwist Bioscience

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy